期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 11, 页码 2570-2579出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2018.1443328
关键词
Acute myeloid leukemia; DCAG; standard dose induction
资金
- National Natural Science Foundation of the People's Republic of China [81070437, 81270614, 81300379, 81370656, 81570134]
- National Public Health Grand Research Foundation [201202017]
- Priority Academic Program Development of Jiangsu Higher Education Institute [JX10231801]
- Key Project of Jiangsu Province Health Agency [K201107]
We retrospectively studied 87 patients aged from 55 to 69 years old with acute myeloid leukemia (AML) who received decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin (DCAG) or standard dose chemotherapy as induction therapy. Patients receiving DCAG had a similar overall response rate (ORR) (p = .6105) and complete remission (CR) rate (p = .3615) compared to those undergoing standard induction. The median overall survival (OS) and relapse-free survival (RFS) was also similar between the two groups although more 'older' (aged from 60 to 69 years old) and 'unfit' patients underwent DCAG regimen. Notably, patients in DCAG group experienced significantly fewer infections (75 versus 100%, p = .001). Moreover recovery of platelet count was significantly more rapid in DCAG group. Thus we speculate DCAG is possibly a feasible and safe treatment regimen for the relatively older patients with AML and is as effective as standard induction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据